Ⅲ期非小细胞肺癌放化疗后原发肿瘤代谢体积需缩小多少才能改善生存:单中心经验
该单中心研究分析了60例ⅢA-B期非小细胞肺癌患者放化疗前后18F-FDG-PET/CT原发肿瘤代谢体积(PT-MV)缩小与生存的相关性,52例(87%)在放化疗结束后6周复查PET/CT。PT-MV缩小至少80%(完全及主要代谢缓解)与生存改善显著相关,中度代谢缓解与生存改善无显著相关。
要点
- 放化疗后PT-MV缩小至少80%与生存改善显著相关(p=0.021,HR 0.36,95%CI 0.15-0.86)。
- 中度代谢缓解(PT-MV缩小50-79%)与生存改善无显著相关(p=0.522)。
- 不同代谢缓解组间总生存差异有统计学意义(p=0.008)。
核心结论
- 在该单中心局部晚期非小细胞肺癌患者队列中,放化疗后PT-MV缩小至少80%(完全及主要代谢缓解)是显著改善患者结局所必需的。
研究设计与样本
- 单中心分析60例连续纳入的ⅢA-B期(UICC第7版)非小细胞肺癌患者,均接受放化疗,并在同一机构于治疗前及治疗后6周行18F-FDG-PET/CT。
- 分析完全缓解(PT-MV缩小100%)、主要缓解(缩小80-99%)、中度缓解(缩小50-79%)、轻微缓解(缩小1-49%)和无缓解(摄取无变化或增高)与生存参数的相关性。
主要发现
- 60例患者中52例(87%)在放化疗结束后6周复查PET/CT。
- 完全代谢缓解10例(17%),主要代谢缓解16例(27%),中度代谢缓解15例(25%),轻微代谢缓解4例(7%),无缓解7例(12%)。
- 全队列中位总生存为17个月(95%CI 11.9-22.1个月)。
- 完全、主要、中度、轻微和无缓解患者的中位总生存分别为34个月(95%CI 0-84.1)、22个月(95%CI 14.2-29.8)、12个月(95%CI 0.4-23.6)、11个月(95%CI 0.2-21.8)和17个月(95%CI 6.7-27.3),p=0.008。
- 多因素分析中,ECOG体能状态(p=0.035,HR 0.49,95%CI 0.25-0.95)以及完全和主要代谢缓解作为连续变量(PT-MV缩小至少80%)(p=0.021,HR 0.36,95%CI 0.15-0.86)为生存的显著预测因素;中度代谢缓解与结局改善无显著相关(p=0.522)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We analysed a correlation between pre- to post-treatment primary tumour metabolic volume (PT-MV) reduction on 18F-FDG-PET/CT and survival in non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy (CRT). METHODS: Sixty consecutive patients with NSCLC stage IIIA-B (UICC 7th edition), treated with chemoradiotherapy, who underwent 18F-FDG-PET/CT at the same institution before and 6 weeks after treatment, were analysed. Different metabolic response values were investigated on their correlation with survival parameters: complete response (100% PT-MV reduction); major response (80-99% PT-MV reduction); moderate response (50-79% PT-MV reduction); minor response (1-49% PT-MV reduction) and non-response (no change or increase in uptake). RESULTS: From 60 patients, 52 (87%) had repeat PET/CT scans 6 weeks after completion of CRT. Complete metabolic response (CR) was reached in ten (17%), whereas major and moderate metabolic responses occurred in 16 (27%) and 15 (25%) patients, respectively. Four patients (7%) had minor metabolic response. Non-response was documented in seven patients (12%). Median overall survival (MS) for the entire cohort was 17 months (95% CI: 11.9-22.1 months). MS according to the different metabolic response values was as follows: 34 months (95% CI: 0-84.1); 22 months (95% CI: 14.2-29.8); 12 months (95% CI: 0.4-23.6); 11 months (95% CI: 0.2-21.8) and 17 months in patients with complete, major, moderate, minor and non-response (95% CI: 6.7-27.3), respectively (p = 0.008). On multivariate analysis, significant predictors of survival included ECOG performance status (p = 0.035, HR 0.49, 95% CI: 0.25-0.95) as well as complete and major metabolic response as a continuous variable with PT-MV reduction of at least 80% (p = 0.021, HR 0.36, 95% CI: 0.15-0.86). Moderate metabolic response did not correlate with improved outcome (p = 0.522). CONCLUSIONS: In this homogeneous locally-advanced NSCLC single-centre patient cohort, a PT-MV reduction of at least 80% (complete and major metabolic response) following CRT was necessary to significantly improve patient outcome.
引用
- Roengvoraphoj O, Eze C, Wijaya C, et al. How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. Eur J Nucl Med Mol Imaging. 2018. PMID: 29876620. doi:10.1007/s00259-018-4063-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。